Modern approach to resistant acromegaly
Authors:
- 15 February 2023
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 80 (2) , 303-307
Abstract
Background Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality with a multimodal/multidisciplinary approach. Despite significant technological and pharmacological progress, still several patients with acromegaly bear a resistant somatotroph adenoma and active disease may persist for many years with resultant poor clinical outcomes. Aim To review briefly definition and pathophysiology of resistance to acromegaly treatment and the options of medical treatment in this context, exploring the role of novel clinical and molecular biomarkers in the personalization of therapy and proposing updates to the currently available guidelines for the treatment of resistant GH-secreting adenomas. Conclusions In the last few years, in parallel with the increased number of medical options available for the therapy of acromegaly, relevant advances occurred in the understanding of the role of novel molecular and clinical biomarkers in predicting the responsiveness to second-line medical treatments, such as Pegvisomant and Pasireotide LAR, and helping clinicians in the personalization of the follow-up and treatment of resistant somatotroph adenomas. The integration of these findings into the existing guidelines may represent a possibly important step forward in the management of “difficult” acromegaly patients.Keywords
This publication has 46 references indexed in Scilit:
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in AcromegalyPLOS ONE, 2012
- Influence of diabetes mellitus on vertebral fractures in men with acromegalyEndocrine, 2011
- A Consensus on Criteria for Cure of AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2010
- High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trialEuropean Journal of Endocrinology, 2009
- Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly StudiesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic reviewPituitary, 2009
- Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary AdenomasThe Journal of Clinical Endocrinology & Metabolism, 2008
- Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegalyClinical Endocrinology, 2002
- THE PHARMACOLOGICAL ASPECTS OF THE TREATMENT OF ACROMEGALYPharmacological Research, 1996
- Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotideThe American Journal of Cardiology, 1995